March 2015

The profound changes under way in the treatment of leukemia were among the highlights captured in our coverage of the 19th Annual International Congress on Hematologic Malignancies:® Focus on Leukemias, Lymphomas, and Myeloma.

Alok A. Khorana, MD, specializes in predictive factors in gastrointestinal oncology and in cancer-associated thrombosis at the Cleveland Clinic. He provided insight on gastric cancer research in an interview with OncLive.

Maurie Markman, MD, offers examples of clinical trials where the interpretation of study results is worthy of considerable additional discussion or where justification for the actual conduct of the study can be called into question.

Research and development in lymphomas are proliferating at such an accelerated pace that the promise of biomarker-driven targeted therapies is moving closer toward reality.

Dennis J. Slamon, MD, PhD, has had an immeasurable impact on the treatment of women with breast cancer by developing trastuzumab (Herceptin) and helping to launch the era of targeted therapies. He was honored in the Breast Cancer category with a 2014 Giants of Cancer Careâ„¢ award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.